echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurol: Poor tolerability, negative efficacy-bexarotene is not recommended for the treatment of relapsing-remitting multiple sclerosis (CCMR ONE)

    Lancet Neurol: Poor tolerability, negative efficacy-bexarotene is not recommended for the treatment of relapsing-remitting multiple sclerosis (CCMR ONE)

    • Last Update: 2021-11-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    The most effective strategy for preserving demyelinated axons is to promote endogenous remyelination


    Another positive regulator of the differentiation of oligodendrocyte precursor cells is the retinoic acid X receptor (RXR) , which is expressed in remyelinating multiple sclerosis lesions in cells of the oligodendrocyte lineage



    Randomized, double-blind, placebo-controlled, parallel grouped Phase 2a trial (CCMR One)

    • Between January 17, 2017 and May 17, 2019, 52 participants were randomly assigned to receive bexarotene (n=26) or placebo (n=26)


      The study does not recommend the use of bexarotene to treat patients with multiple sclerosis because it is poorly tolerated and the main efficacy result is negative


      SoSTART Collaboration.
      Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial.
      Lancet Neurol.
      2021;20(10):842- 853.
      doi:10.
      1016/S1474-4422(21)00264-7

      Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.